^
Association details:
| Biomarker: | KRAS mutation + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
335P - Resistance to CDK4/6 inhibitors: Clinical practice use of liquid biopsy to identify KRAS-mutations in ctDNA and overexpression of CDK9 in plasma derived exosomes
Published date:
09/14/2020
Excerpt:
A total of 948 blood samples were collected from 106 pts with HR+/HER2-MBC treated with P+F as first-line metastatic therapy...detection of KRAS ctDNA was significantly associated with resistance, recurrence and prognosis (p<0.001).
Secondary therapy:
fulvestrant
